AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02899702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRIVIGEN (CSL Behring)
Description: Single administration of intravenous immunoglobulin solution Privigen® (CSL Behring AG, Bern, Switzerland) at a dose of 2g / kg. IGIV 2g/kg within 12 hours following PICU admission (or outbreak of first shock signs).~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study.
Study NCT02899702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin
Description: 4%(LFB) ALBUMIN Single administration of human Albumin 4% diluted albumin (VIALEBEX® LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg (4gG, 100 ML, Sodium chloride 0.61 G / 100ML Water for injections QSP 100 ML Sodium caprylate 0.3 G / 100ML) We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study.
Study NCT03902834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Use the wearable technology (Fitbit) and proven behavioural change techniques to precondition patients prior to lung cancer surgery
Study NCT00391625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA-GCB
Description: 15-60 U/kg every other week via intravenous infusion
Study NCT00410605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00410605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study NCT00410605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study NCT03935152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule
Study NCT04503629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole Sodium
Description: Anaprazole Sodium 20mg
Study NCT04503629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole Sodium
Description: Anaprazole Sodium 40mg
Study NCT04503629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole sodium
Description: Rabeprazole sodium 10mg
Study NCT03110783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bioseal
Description: Upon completion of the sutured dural repair, the closure will be evaluated for intra-operative CSF leakage with a baseline Valsalva maneuver to 10-20 cm H2O for 5-10 seconds. Subjects who have a CSF leak will be enrolled into the study. If randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds.
Study NCT05711589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CBA was performed under intracardiac echocardiography guidance without fluoroscopy
Description: Zero-X group: Patients undergoing ICE-guided CBA
Study NCT05711589 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cryoablation (CBA) was performed under fluoroscopic guidance
Description: cryoablation (CBA) was performed under fluoroscopic guidance
Study NCT01812265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: single Dose
Study NCT01763502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FOOD
Description: The food transfers consist of multiple-micronutrient-fortified corn soy blend (CSB), oil, and sugar, totaling approximately 1200 calories per day per child and including 99% of iron requirements.
Study NCT01763502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CASH
Description: Cash transfers equal the estimated value of the food basket if purchased in the market.
Study NCT01812265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Dose
Study NCT00787280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Ketogenic Diet (LCKD)
Description: participants will follow a low carbohydrate ketogenic diet for six weeks
Study NCT00787280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Fat Diet (LFD)
Description: particpants will follow a low fat diet for six weeks
Study NCT01414686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Commercially-Available Interactive Video Games
Description: Two commercially available gaming platforms were used in this study, the Nintendo Wii and the Sony PS 2. The Wii games included Wii Sports and Wii Fit; PS games included the EyeToy Play 2 and Kinetic. Each of these games provides multiple mini games which pose different movement challenges, including dynamic balance, speed, accuracy, general mobility, and weight shifts.~Game play was performed 1 hour/day, 4 days/ week, for a period of 5 weeks, totaling 20 hours.
Study NCT03389490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine 300 UNT/ML
Description: Self titration of insulin glargine U300
Study NCT03389490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neutral protamine hagedorn insulin
Description: Self titration of NPH insulin
Study NCT01074086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD 001
Description: RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg
Study NCT00501865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW273225
Description: GW273225 will be available as white tablets containing 25 mg GW273225.The study drug will be taken with 240 milliliters of water at room temperature.
Study NCT00696839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: 3 sessions of CBT: introduction of CBT, training in relaxation and guided imagery, and troubleshooting/closure. 50 minute sessions with an HIV-experienced treating psychologist in Beck-type CBT. Participants will be given an audiorecording of the 2nd session to be used in private home practice, as desired.
Study NCT00180583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guidant GALILEO Intravascular Radiotherapy System
Description: Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
Study NCT00500825 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement of Resting Energy Expenditure
Description: Non-invasive measurement of Resting Energy Expenditure
Study NCT04735991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kapok Initiative
Description: The detailed process is:~1. After randomization, the Kapok assistant will contact the patient's family~2. The family of the patient joins the Kapok Initiative. They will participate in a 60-minute training program for 27 days, which is taught online by experts; The contents of the lectures are as follows: 1) Doctors are also mortal; 2) New medicines and new therapies; 3) Alternative therapies; 4) Don't panic during the operation; 5) Pain relief; 6) Side effects of treatment; 8) About the truth; 9) New topics; 10) Anti-cancer cost-effectiveness; 11) Medical insurance; 12) Commercial medical insurance; 13) Exercise and rehabilitation; 14) Nutrition and Foods to increase leukocytes level; 15) Long-term persistence; 16) Acceptance Change; 17) Two new roles; 18) Future expectation.
Study NCT03029091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Potassium
Description: Losartan potassium
Study NCT02449590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Onion powder
Description: Hot meals with onion powder; 10 g/day onion powder corresponding to 100 g/day fresh onion in meals with potato and beef Intervention period 14 days.
Study NCT02449590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hot meals without onion powder; Control meal with potato, beef, soy protein, and sucrose to match macronutrient composition of active treatment
Study NCT00604045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Description: The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
Study NCT00604045 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Condition (ACC)
Description: The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
Study NCT03220386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Decolonization by nasal Octinidin treatment and skin washings
Description: Patients receive nasal Octinidin treatment and skin washings for five consecutive days
Study NCT03916081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast Cream 0.05%
Description: Roflumilast 0.05% cream for topical application
Study NCT03916081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast Cream 0.15%
Description: Roflumilast 0.15% cream for topical application
Study NCT03916081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Inactive vehicle cream matched to roflumilast cream for topical application.
Study NCT01240135 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FID 114675A multi-purpose disinfecting solution (MPDS)
Description: Daily regimen, 14 days: Thoroughly wet and rub each side of study contact lens for 10 seconds, rinse each side of the lens for 10 seconds, and soak contact lens for at least 6 hours.
Study NCT01240135 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: renu fresh Multi-Purpose Solution (MPS)
Description: Daily regimen, 14 days: Wet study contact lens with 3 drops and rub each side of the lens for 20 seconds, rinse each side of the lens for 5 seconds, and soak contact lens for at least 4 hours.
Study NCT01240135 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A contact lenses (Acuvue Advance)
Description: A fresh pair of contact lenses matching subject's pre-study lenses, including parameters, dispensed at the beginning of each period for daily wear, minimum 8 hours per day, 14 days.
Study NCT03640221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: The sodium-glucose cotransporter 2 (SGLT2) inhibitors are an exciting new class of antidiabetic drugs that cause a modest reduction in high blood pressure and large reductions in the risk of cardiovascular disease (CVD) outcomes and renal outcomes in patients with advanced type 2 diabetes and very high CVD risk. However, the mechanistic underpinning of these CVD benefits is not well understood. this arm will allow us to test our hypothesis.
Study NCT03640221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 12.5mg
Description: comparator arm allow us to mimic the mild anti hypertensive effect seen with the SGLT-2 inhibitors in order to enable us to differentiate whether the cardiovascular protection seen with the SGLT-2 inhibitors is secondary to its antihypertensive effects vs the potential decrease in sympathetics.
Study NCT03640221 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microneurography
Description: Multiunit recordings of postganglionic sympathetic nerve activity will be obtained with unipolar tungsten microelectrodes inserted selectively into skeletal muscle nerve fascicles of the peroneal nerve. The nerve signals are amplified, filtered (bandwidth 700-2000 Hz), rectified and integrated to obtain a mean voltage display of sympathetic nerve activity. Sympathetic bursts are counted by inspection of the neurograms. A deflection on the mean voltage display is counted as a burst if it has a minimal signal to noise ratio of 2:1. The interobserver and intraobserver variations in identifying bursts are \<10% and \< 5%, respectively.
Study NCT03640221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneurography
Description: Multiunit recordings of postganglionic sympathetic nerve activity will be obtained with unipolar tungsten microelectrodes inserted selectively into skeletal muscle nerve fascicles of the peroneal nerve. The nerve signals are amplified, filtered (bandwidth 700-2000 Hz), rectified and integrated to obtain a mean voltage display of sympathetic nerve activity. Sympathetic bursts are counted by inspection of the neurograms. A deflection on the mean voltage display is counted as a burst if it has a minimal signal to noise ratio of 2:1. The interobserver and intraobserver variations in identifying bursts are \<10% and \< 5%, respectively.
Study NCT03640221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SKNA recordings
Description: SKNA recordings will be captured by placing ECG electrodes on the chest wall. Recordings will be obtained simultaneously with microneurographic recording. The two techniques will undergo identical filtering and processing of the neurophysiologic inputs which are then displayed simultaneously using identical output functions.
Study NCT03640221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SKNA recordings
Description: SKNA recordings will be captured by placing ECG electrodes on the chest wall. Recordings will be obtained simultaneously with microneurographic recording. The two techniques will undergo identical filtering and processing of the neurophysiologic inputs which are then displayed simultaneously using identical output functions.
Study NCT03640221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Handgrip
Description: Subjects will perform static handgrip at 33% MVC for 2 minutes, using a Stoelting recording handgrip dynamometer. Force output will be recorded continuously and displayed on the computer screen in real time to provide the subject with visual feedback. MVC will be determined for each subject at the beginning of each experiment. Subjects will be instructed to avoid straining maneuvers, changes in breathing, and contraction of non-exercising muscles during the experimental protocols. Ratings of perceived exertion (RPE) will be obtained at the end of each exercise by using a 6- to 20-unit Borg scale. Static handgrip at 33% MVC is accompanied by reflex increases in muscle sympathetic nerve activity caused by activation of the acid-sensing unmyelinated muscle afferents.
Study NCT03640221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Handgrip
Description: Subjects will perform static handgrip at 33% MVC for 2 minutes, using a Stoelting recording handgrip dynamometer. Force output will be recorded continuously and displayed on the computer screen in real time to provide the subject with visual feedback. MVC will be determined for each subject at the beginning of each experiment. Subjects will be instructed to avoid straining maneuvers, changes in breathing, and contraction of non-exercising muscles during the experimental protocols. Ratings of perceived exertion (RPE) will be obtained at the end of each exercise by using a 6- to 20-unit Borg scale. Static handgrip at 33% MVC is accompanied by reflex increases in muscle sympathetic nerve activity caused by activation of the acid-sensing unmyelinated muscle afferents.
Study NCT03640221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-handgrip forearm vascular occlusion
Description: This will be performed by inflating a pneumatic cuff on the upper exercising arm to suprasystolic pressure (220 mmHg) beginning 10 seconds before the subject stops gripping and ending 2 minutes into the post-exercise period. The vascular occlusion maintains intramuscular acidosis and thus the stimulation of acid-sensing unmyelinated skeletal muscle afferents and their reflex increase in muscle sympathetic nerve activity and BP, while the muscular relaxation eliminates central command and the attendant increase in heart rate (which returns to the baseline level). As soon as the cuff is release and the forearm circulation is restored, muscle sympathetic nerve activity quickly returns to the baseline level and BP soon follows.
Study NCT03640221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-handgrip forearm vascular occlusion
Description: This will be performed by inflating a pneumatic cuff on the upper exercising arm to suprasystolic pressure (220 mmHg) beginning 10 seconds before the subject stops gripping and ending 2 minutes into the post-exercise period. The vascular occlusion maintains intramuscular acidosis and thus the stimulation of acid-sensing unmyelinated skeletal muscle afferents and their reflex increase in muscle sympathetic nerve activity and BP, while the muscular relaxation eliminates central command and the attendant increase in heart rate (which returns to the baseline level). As soon as the cuff is release and the forearm circulation is restored, muscle sympathetic nerve activity quickly returns to the baseline level and BP soon follows.
Study NCT03640221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Testing of the Arterial Baroreflex Function
Description: We will compare effects of Ertugliflozin vs. low-dose HCTZ on sinoaortic baroreflex function in hypertensive diabetic subjects during both spontaneous fluctuations in arterial pressure and during decreases and increases in arterial pressure induced by the Valsalva maneuver. The aim of this protocol is to determine if the sympathetic nerve, as well as the heart rate, component of the sinoaortic baroreflex can be augmented by the SGLT2 inhibitor. After obtaining stable baseline recordings, arterial pressure, heart rate, and muscle sympathetic nerve activity will recorded during spontaneous fluctuations in BP over 5 minutes and during both decreases in BP during phase III of the Valsavla maneuver and during the phase IV overshoot in BP upon its release. Frequent accurate measurement of arterial pressure will be obtained with a highly-rated oscillometric arm monitor that records 6 BP readings per minute (Welch Allyn Vital Signs Monitor).
Study NCT03640221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing of the Arterial Baroreflex Function
Description: We will compare effects of Ertugliflozin vs. low-dose HCTZ on sinoaortic baroreflex function in hypertensive diabetic subjects during both spontaneous fluctuations in arterial pressure and during decreases and increases in arterial pressure induced by the Valsalva maneuver. The aim of this protocol is to determine if the sympathetic nerve, as well as the heart rate, component of the sinoaortic baroreflex can be augmented by the SGLT2 inhibitor. After obtaining stable baseline recordings, arterial pressure, heart rate, and muscle sympathetic nerve activity will recorded during spontaneous fluctuations in BP over 5 minutes and during both decreases in BP during phase III of the Valsavla maneuver and during the phase IV overshoot in BP upon its release. Frequent accurate measurement of arterial pressure will be obtained with a highly-rated oscillometric arm monitor that records 6 BP readings per minute (Welch Allyn Vital Signs Monitor).
Study NCT02168608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemia precondition
Description: Three cycles of 5-min ischemia/5-min reperfusion induced by a blood pressure cuff placed on the right upper arm served as RIPC stimulus.
Study NCT02168608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: None remote ischemia precondition
Description: Placed an uninflated cuff on the right upper arm for 30 min.
Study NCT02683863 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BG00012 (DMF) (Tecfidera®.)
Description: Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.
Study NCT05185908 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement of the optic nerve sheath diameter by ultrasound-guidance.
Description: Measurement of the optic nerve sheath diameter (ONSD) by ultrasound guidance can be used in the diagnosis of increased ICP. The investigators interrogated the effects of lateral 45° downward position and CO2 insufflation on ONSD in patients undergoing laparoscopic transperitoneal nephrectomy.
Study NCT02205580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion
Study NCT02205580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion
Study NCT02205580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion
Study NCT01973205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 250 mg and Aspirin 250 mg
Description: 2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
Study NCT01973205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets